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Abstract
Objectives
To determine whether genetic variation within genes related to the Toll-like receptor, inflam-
masome and interferon-γ pathways contributes to the differences in treatment response to
tumour necrosis factor inhibitors (anti-TNF) in patients with rheumatoid arthritis (RA).
Methods
In a retrospective case-case study, we assessed 23 functional single nucleotide polymor-
phisms (SNPs) in 15 genes. We included 538 anti-TNF naïve Danish RA patients from the
nationwide DANBIO database. Multivariable logistic regression analyses were performed to
detect associations (p-value<0.05) between genotypes and European League Against
Rheumatism (EULAR) treatment responses. False Discovery Rate corrections for multiple
testing (q-value) and stratified analyses were performed to investigate association with indi-
vidual therapies and IgM-rheumatoid factor (RF) status.
Results
Six of twenty successfully genotyped polymorphisms were nominally associated with
EULAR treatment response. Three of these were in weak to moderate linkage
PLOSONE | DOI:10.1371/journal.pone.0139781 October 6, 2015 1 / 13
OPEN ACCESS
Citation: Sode J, Vogel U, Bank S, Andersen PS,
Hetland ML, Locht H, et al. (2015) Genetic Variations
in Pattern Recognition Receptor Loci Are Associated
with Anti-TNF Response in Patients with Rheumatoid
Arthritis. PLoS ONE 10(10): e0139781. doi:10.1371/
journal.pone.0139781
Editor: Masataka Kuwana, Nippon Medical School
Graduate School of Medicine, JAPAN
Received: March 5, 2015
Accepted: September 17, 2015
Published: October 6, 2015
Copyright: © 2015 Sode et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This study was supported by the Danish
Rheumatism Association, R95-A1913/R99-A1923
(www.gigtforeningen.dk), Region of Southern
Denmark’s PhD Fund, 12/7725 (www.
regionsyddanmark.dk) and the Department of
Rheumatology, Frederiksberg Hospital (www.
frederiksberghospital.dk). The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
disequilibrium with polymorphisms previously reported associated with anti-TNF treatment
response. TLR5(rs5744174) variant allele carriers (odds ratio(OR) = 1.7(1.1–2.5),p = 0.010,
q = 0.46) and TLR1(rs4833095) homozygous variant carriers (OR = 2.8(1.1–7.4),p = 0.037,
q = 0.46) had higher odds for a positive treatment response. NLRP3(rs10754558) variant
allele carriers (odds ratio(OR) = 0.6(0.4–1.0),p = 0.045,q = 0.46) were more likely to have a
negative treatment response.
The association in TLR5(rs5744174) remained significant after correction for multiple
comparisons among patients negative for RF (OR = 6.2(2.4–16.3),p = 0.0002,q = 0.024).
No other association withstood correction for multiple testing. Post hoc analyses showed
that change in Patient Global score on a visual analogue scale (VAS) and change in pain
VAS were the main factors responsible for the association.
Conclusions
We reproduced previously reported associations between genetic variation in the TLR10/1/
6 gene cluster, TLR5, and NLRP3 loci and response to anti-TNF treatment in RA. Changes
in VAS pain and patient global scores were the main contributors to the association found
for TLR5. Furthermore, we identified other candidate genes that require replication in inde-
pendent cohorts.
Introduction
Predictive biomarkers capable of stratifying patients into responders and non-responders to
treatment with tumour necrosis factor inhibitors (anti-TNF) will enable selection of the opti-
mal treatment for the individual patients and thereby improve patient care. Such biomarkers,
however, are scarce and none are applicable in a clinical setting. Some single nucleotide poly-
morphisms (SNPs) may show associations with anti-TNF response and might be useful for
prediction but despite several studies addressing this issue, only few associations have been rep-
licated (e.g. the PTPRC [1] and PDE3A–SLCO1C1 loci [2]). Overall, associations between
genetic polymorphisms and anti-TNF response are characterized by small effect sizes.
However, together with e.g. expression profiling, epigenetic, para-clinical, or clinical mark-
ers the growing number of polymorphisms associated with anti-TNF treatment response may
be potentially useful for prediction [3]. Furthermore, associations between genetic variation
and treatment outcome may provide insight into aberrant molecular pathways and thus form
the basis for developing new treatment strategies.
We recently published a candidate gene study [4] focussing on genes involved in the NF-κB
mediated signalling pathway. Polymorphisms associated with anti-TNF response were found
in the genes encoding NACHT, LRR and PYD domains-containing protein 3 (NLRP3/NALP3)
(rs4612666) and interferon-γ (IFN-γ) (rs2430561). The association with NLRP3 is supported
by a recent study of British patients [5].
The NLRP3 inflammasome belongs to a group of intracellular innate immune sensors,
which generally sense stimuli associated with infection and stressed tissue [6]. Caspase recruit-
ment domain-containing protein 8 (CARD8) is involved in NLRP3-inflammasome formation
[6] and polymorphisms in this gene have been associated with response to anti-TNF drugs [5].
Upon inflammasome activation, caspase–1 proteolytically activates the pro-inflammatory cyto-
kines interleukin (IL)-1β and IL–18.
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Like the NLRP3-inflammasome, Toll-like receptors (TLRs) are innate immune sensors.
They sense exogenous and endogenous antigens and activate pathways (e.g. NF-κB, AP–1)
that increase production of pro-inflammatory cytokines. A recent well-powered study found
polymorphisms in the TLR signalling pathways (TLR2, TLR4,MyD88, CHUK) associated with
response to anti-TNF treatment [7]. Also, polymorphisms in the genes encoding TLR–1 and
TLR–5 (rs5744174) have been shown to be associated with increased IFN-γ secretion [8,9],
and, for the latter, with reduced expression of IL–6 and IL–1β [10].
Interferon-γ (IFN-γ) is a central cytokine for both adaptive and innate immunity that medi-
ates downstream signalling through binding to the heterodimeric IFN-γ receptor (IFNGR1
and IFNGR2), which in turn activates the JAK-STAT (Janus kinase Signal Transducers and
Activator of Transcription) pathway [11]. STAT4 regulates proliferation, survival, and differ-
entiation of lymphocytes and genetic variation in the corresponding gene has been associated
with RA [12].
Thus, our aim in this study was to assess additional functional polymorphisms related to the
TLR, inflammasome and interferon-γ pathways and thereby extend the analysis of associations
found in our previous study [4]. We analysed 23 functional polymorphisms in CARD8,
IFNGR1, IFNGR2, IL12B, IL12RB1, IL12RB2, IL17A, IL18, JAK2, NLRP1, NLRP3, TBX21,
TIRAP, TLR1 and TLR5 in a Danish cohort of 538 RA patients treated with anti-TNF and pro-
spectively monitored for treatment effect using validated clinical scoring methods.
Materials and Methods
Ethics statement
The study was conducted in accordance with the Declaration of Helsinki and was approved by
the Regional Ethics Committee of Central Denmark Region (M–20100153 and S–20120113)
and the Danish Data Protection Agency (J. 2010-41-4719). The Regional Ethics Committee of
Central Denmark Region gave exemption from obtaining informed consent because samples
were taken for other reasons and data were analysed anonymously.
Patients and Samples
We included 538 anti-TNF naïve RA patients. All patients initiated their first anti-TNF treat-
ment, had clinical variables registered at baseline and follow-up in DANBIO (The National
Danish Registry for Biological Treatment of Rheumatic Diseases), and had available blood
samples. The baseline (pre-treatment) visit was defined as a visit 0–30 days before onset of
anti-TNF treatment and follow-up as a visit within 60–180 days after treatment onset (at the
contact closest to 120 days if more than one visit was registered). A detailed description of the
DANBIO registry and the additional patient data were published previously [4,13].
Candidate gene analysis
PubMed was searched for functional polymorphisms in genes closely related to the up- and
down-stream signalling molecules of the NLRP3 inflammasome and interferon-γ [4]. A total
of 23 SNPs were ultimately chosen primarily based on evidence of biological effect and sec-
ondly based on documented association with autoimmune disease (S1 Table). Expected minor
allele frequencies (MAFs) ranged from 14% to 44% except for one polymorphism (rs11810249,
MAF: 4.4%).
The polymorphisms were genotyped by PCR-based KASP genotyping assay by LGC Geno-
mics (Middlesex, United Kingdom—www.lgcgenomics.com) on DNA extracted from blood
(Maxwell 16 LEV Blood DNA Kit, Promega, Madison, Wisconsin, USA) as described by Bank
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et al. [14]. Genotyping failed for rs8134145 (IFNGR2) and rs2072493 (TLR5) due to their close
proximity to neighbouring genotyped SNPs, and for IL17A for unknown reasons. All other
chosen assays had a call rate exceeding 95%. Repeated genotyping of 94 randomly selected
samples in an inflammatory bowel disease cohort yielded>99% identical calls.
Statistical methods
Primary outcome (good, moderate or none) was defined by the European League Against
Rheumatism (EULAR) response criteria [15] at follow-up. We performed the analyses by com-
paring either EULAR good/moderate vs. none (G/M vs. N) response or EULAR good vs. mod-
erate/none (G vs. M/N) response. We also analysed treatment response defined by the
American College of Rheumatology outcome measure, ACR50 response [16] and relative
change in disease activity score for 28 joints (DAS28) (relDAS28 = (baseline DAS28 − follow-up
DAS28)/baseline DAS28) to enable comparison with other studies.
Multivariate logistic regression analyses were performed to assess association between geno-
type and anti-TNF treatment response at the 5% significance level. Adjustments were made in
the multivariate analyses for sex, baseline health assessment questionnaire (HAQ) score,
DAS28 and concomitant treatment with disease modifying anti-rheumatic drug (DMARD).
We have also performed stratified analyses for patients positive for IgM-RF (seropositive RA
patients), for the specific type of anti-TNF drug (not certolizumab and golimumab due to
insufficient power) and for a combined group of patients treated with monoclonal antibodies
(infliximab, adalimumab, and golimumab).
We performed correction for multiple testing using False Discovery Rate classical one-stage
method set at 0.05 (q-value) [17]. Values were based on the number of test performed in each
of the primary, secondary and stratified analyses, respectively (see S1–S6 tables). Values can be
interpreted as the expected proportion of false positive results at least as extreme as the
observed result.
Results
Study population
Baseline characteristics and treatment response of the study population are presented in
Table 1. Seronegative RA patients were significantly younger and had higher pain and global
scores as well as higher tender joint count compared with the seropositive patients. No differ-
ence in response rates to anti-TNF was observed between the two groups. Both had 29–30%
non-responders. Patients with RA receiving concomitant synthetic DMARDs (sDMARD)
comprised 84%.
Clinical data were collected at variable time-points due to the study design. Eighty-seven
per cent of the patients had baseline data collected 7 days or less before treatment onset, and
74% of the follow-up data were registered 16±4 weeks after treatment onset (S1 Fig).
Genotype associations with anti-TNF response
We assessed the association with EULAR anti-TNF response regardless of RF status among all
patients. We found that variant allele carriers of the TLR5 rs5744174 (OR = 1.7, p = 0.010),
IL18 rs187238 (OR = 1.5, p = 0.026) and the homozygous variant genotype of TLR1 rs4833095
(OR = 2.8, p = 0.037) had a positive treatment response (EULAR G vs. M/N) (Table 2). With
EULAR G/M vs. N as treatment response, carriers of another variant in IL18 (rs1946518; r2 =
0.59) were more likely to have positive treatment response (OR = 1.6, p = 0.022). Furthermore,
individuals heterozygous for IL12B rs6887695 (OR = 0.6, p = 0.017) and variant allele carriers
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Table 1. Baseline clinical characteristics and treatment response of the study population.
All RA patients Seropositive RA patients Seronegative RA patients P-value #
Number 538 407 (75.7%) 131 (24.3%)
Female 407 (75.7%) 302 (74.2%) 105 (80.2%) 0.17
Mean age / years (SD)
at treatment start 55.0 (13.0) 55.7 (12.8) 53.0 (13.6) 0.04
Smoking status
Current 142 (31.8%) 110 (32.7%) 32 (29.1%) 0.56
Previous 151 (33.9%) 120 (35.7%) 31 (28.2%) 0.20
Never 153 (34.3%) 106 (31.6%) 47 (42.7%) 0.03
Missing data 92 (-) 71 (-) 21 (-) 0.71
Synthetic DMARD at baseline 452 (84.0%) 342 (84.0%) 110 (84.0%) 0.99
Number of synthetic DMARDs (1/2/3) 61.7%/16.4%/5.9% 61.7%/16.0%/6.4% 61.8%/17.6%/4.6% ns.
Methotrexate 396 (73.6%) 299 (73.5%) 97 (74.0%) 0.90
Salazopyrine 120 (22.3%) 92 (22.6%) 28 (21.4%) 0.77
Chloroquine 70 (13.0%) 55 (13.5%) 15 (11.5%) 0.54
Leﬂunomide 10 (1.9%) 7 (1.7%) 3 (2.3% 0.67
Azathioprine 8 (1.5%) 6 (1.5%) 2 (1.5%) 0.97
Erosive status
Erosions 308 (65.4%) 258 (70.9%) 50 (46.7%) <0.0001
Missing data 67 (-) 43 (-) 24 (-)
Baseline patient global score (VAS 0–100) / Mean (SD) 62.6 (22.6) 60.8 (22.9) 68.5 (20.7) 0.0006
Δ patient global score / Mean (SD) 22.1 (28.1) 21.6 (1.4) 23.7 (29.5) 0.45
Baseline physician global score (VAS 0–100) / Mean (SD) 38.4 (20.7) 38.0 (20.2) 39.8 (22.3) 0.38
Baseline pain score (VAS 0–100) / Mean (SD) 58.0 (22.8) 55.9 (23.2) 64.4 (20.2) 0.0002
Δ pain score / Mean (SD) 21.4 (28.0) 20.9 (28.0) 22.9 (28.0) 0.48
TJC 0–28 / Mean (SD) 9.5 (7.3) 9.0 (7.0) 11.1 (8.1) 0.004
SJC 0–28 / Mean (SD) 5.4 (4.6) 5.6 (4.5) 4.8 (4.8) 0.08
HAQ score (VAS 0–100) / Mean (SD) 1.2 (0.7) 1.2 (0.7) 1.3 (0.7) 0.72
CRP / mg/mL (SD) 19.7 (25.5) 20.5 (27.0) 17.2 (20.3) 0.20
DAS28 / mean (SD) 4.9 (1.2) 4.8 (1.2) 5.0 (1.1) 0.14
ΔDAS28 / mean (SD) 1.5 (1.4) 1.5 (1.5) 1.5 (1.4) 0.81
Anti-TNF drug
Inﬂiximab (%) 168 (31.2%) 122 (30.0%) 46 (35.1%) 0.27
Etanercept (%) 166 (30.8%) 124 (30.5%) 42 (32.1%) 0.73
Adalimumab (%) 134 (24.9%) 105 (25.8%) 29 (22.1%) 0.40
Golimumab (%) 49 (9.1%) 38 (9.3%) 11 (8.4%) 0.75
Certolizumab (%) 21 (3.9%) 18 (4.4%) 3 (2.3%) 0.27
EULAR response
Good (%) 231 (42.9%) 178 (43.7%) 53 (40.5%) 0.51
Moderate (%) 148 (27.5%) 108 (26.5%) 40 (30.5%) 0.37
None (%) 159 (29.6%) 121 (29.7%) 38 (29.0%) 0.87
ACR50 response (%) 170 (31.6%) 131 (32.2%) 39 (29.8%) 0.61
RelDAS28 response (SD) 0.28 (0.32) 0.28 (0.34) 0.28 (0.27) 0.91
SD: standard deviation; DMARD: disease modifying anti-rheumatic drugs; VAS: visual analogue scale; ΔVAS: baseline VAS minus follow-up VAS; TJC:
tender joint count; SJC: swollen joint count; HAQ: health assessment questionnaire; CRP: C-reactive protein; DAS28: disease activity score (28-joints);
EULAR: European League Against Rheumatism; ACR50: American College of Rheumatology, 50% improvement; RelDAS28: relative change in DAS28;
#: Two-sided t-test p-value of difference in means/proportions between seropositive and seronegative patients; Seropositive: Positive for IgM-RF
doi:10.1371/journal.pone.0139781.t001
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of NLRP3 rs10754558 (OR = 0.6, p = 0.017) seemed to have a less favourable treatment
response (EULAR G/M vs. N).
Analyses of associations with treatment response outcome defined by ACR50 and relDAS28
are shown in S2 Table. Association with altered ACR50 treatment response was found for
TLR1 rs4833095 and with altered relDAS28 treatment responses for NLRP3 rs10754558 and
TLR5 rs5744174.
We also assessed the functionally relevant haplotypes in IFNGR2 and IL12B (S1 Table) for
association with EULAR anti-TNF response (G/M vs. N and G vs. M/N) under the same multi-
variate model. No associations between risk-haplotypes and anti-TNF response and no interac-
tion with smoking were found.
Stratified analyses. Next, we performed stratified analyses of polymorphisms for associa-
tions with treatment response.
Table 2. Adjusted odds ratios for associations between genotypes and EULAR anti-TNF treatment response.
EULAR
G/M vs. N G vs. M/N
Gene Genotype Freq. G/M/N OR (95% CI), p-, q-value OR (95% CI), p-, q-value
SNP
IL12B GG 241 109/70/62
rs6887695 GC 224 91/54/79 0.60 (0.40–0.91), 0.017*, 0.46 0.82 (0.56–1.20), 0.31, 0.70
CC 51 20/22/9 1.44 (0.64–3.22), 0.38, 0.72 0.81 (0.43–1.53), 0.52, 0.74
GC/CC 275 111/76/88 0.69 (0.46–1.03), 0.068, 0.47 0.82 (0.57–1.17), 0.28, 0.65
IL18 GG 254 96/76/82
rs187238 GC 198 91/51/56 1.39 (0.91–2.13), 0.13, 0.48 1.50 (1.02–2.21), 0.041*, 0.46
CC 55 26/16/13 1.85 (0.91–3.74), 0.089, 0.47 1.58 (0.86–2.90), 0.14, 0.48
GC/CC 253 117/67/69 1.48 (0.99–2.21), 0.057, 0.47 1.52 (1.05–2.19), 0.026*, 0.46
IL18 GG 187 73/50/64
rs1946518 GT 246 111/70/65 1.57 (1.02–2.43), 0.041*, 0.46 1.36 (0.92–2.03), 0.13, 0.48
TT 82 36/24/22 1.72 (0.94–3.16), 0.077, 0.47 1.25 (0.73–2.16), 0.42, 0.72
GT/TT 328 147/94/87 1.61 (1.07–2.42), 0.022*, 0.46 1.34 (0.92–1.94), 0.13, 0.48
NLRP3 CC 181 86/50/45
rs10754558 CG 243 96/69/78 0.61 (0.39–0.96), 0.033*, 0.46 0.71 (0.48–1.06), 0.098, 0.48
GG 85 35/24/26 0.75 (0.41–1.36), 0.34, 0.71 0.80 (0.47–1.37), 0.42, 0.72
CG/GG 328 131/93/104 0.64 (0.42–0.99), 0.045*, 0.46 0.74 (0.50–1.07), 0.11, 0.48
TLR1 TT 312 130/91/91
rs4833095 TC 178 75/53/50 1.17 (0.76–1.80), 0.47, 0.72 1.06 (0.72–1.55), 0.78, 0.91
CC 21 14/2/5 1.09 (0.37–3.20), 0.87, 0.92 2.80 (1.07–7.35), 0.037*, 0.46
TC/CC 199 89/55/55 1.16 (0.77–1.76), 0.48, 0.72 1.17 (0.81–1.69), 0.41, 0.72
TLR5 TT 170 61/55/54
rs5744174 TC 234 104/62/68 1.25 (0.80–1.96), 0.33, 0.71 1.55 (1.02–2.35), 0.040*, 0.46
CC 107 53/26/28 1.51 (0.86–2.66), 0.16, 0.50 1.96 (1.18–3.25), 0.009**, 0.46
TC/CC 341 157/88/96 1.32 (0.87–2.02), 0.19, 0.57 1.67 (1.13–2.46), 0.010*, 0.46
Logistic regression, adjusted for gender, HAQ, DMARD, and disease activity score (28-joints) at baseline; CI: conﬁdence interval; Freq.: Frequency; OR:
odds ratio; EULAR, G/M/N: European League Against Rheumatism response criteria, good/moderate/none; P-value:
*<0.05,
**<0.01;
q-value: False Discovery Rate classical one-stage method set at 0.05.
doi:10.1371/journal.pone.0139781.t002
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For seropositive RA patients (n = 407), IL12B rs6887695, IL18 rs187238 and NLRP3
rs10754558 were associated with similar effect estimates and significance levels (S3 Table) as
the total cohort. For IL18 rs1946518 and TLR1 rs4833095 effect estimates were similar (p-value
<0.1) and for TLR5 rs5744174 effect estimates were substantially lower and non-significant
compared to the overall cohort (S3 Table).
Stratified analyses by type of anti-TNF drug (infliximab (n = 168), etanercept (n = 166), ada-
limumab (n = 134) and the combined group of monoclonal antibodies (infliximab, adalimumab,
and golimumab) (n = 372)) are shown in S4 Table. Variant allele carriers of TLR5 rs5744174
treated with infliximab (OR = 2.7, p = 0.018) and etanercept (OR = 2.3, p = 0.022) were more
likely to have a good treatment response (EULAR G vs. MN) (S4 Table) and a clear allele-dosage
effect was observed. Altered treatment responses were also seen among variant allele carriers of
NLRP1 (rs878329) andNLRP3 rs10754558 treated with infliximab and among variant allele car-
riers of IL12B rs6887695 treated with the monoclonal anti-TNF drugs (S4 Table).
Post hoc analyses. Since there was some discrepancy between associations found in the
primary analyses and stratified analyses of seropositive patients, we also assessed the associa-
tion in the seronegative subgroup of RA patients for TLR5 rs5744174 (S3 Table). Seronegative
carriers of the variant allele of TLR5 rs5744174 had a greater chance of good treatment
response (EULAR G vs. M/N) (OR = 6.2 (2.4–16.3), p = 0.0002, q = 0.024) (Fig 1).
Due to lack of association among seropositive RA patients with the TLR5 polymorphism,
we explored other clinical variables of importance for this association using linear regression
analyses of the association between the TLR5 polymorphism and the components of DAS28
(change (Δ) between baseline and follow-up of swollen and tender joint counts (SJC and TJC),
CRP and patient global score).
Interestingly, TLR5 rs5744174 was strongly associated with Δ patient global score but nei-
ther with Δ SJC (p = 0.66), Δ TJC (p = 0.20) nor with Δ CRP (p = 0.22). Using linear regression
the association remained stable both in a crude analysis (regression coefficient (RC) = 7.8 (2.7–
12.8), p-value = 0.003) and in a multivariate model adjusting for baseline patient global score
plus the same variables as in the primary analyses (RC = 7.4 (2.6–12.1), p = 0.002). Almost
identical results were found when we substituted Δ patient global score with Δ pain score in a
similar analysis (RC = 6.8 (95% CI: 2.2–11.4), p = 0.004).
In this cohort of RA patients, there were marked clinical differences between the seroposi-
tive and seronegative subgroups (fraction of smokers, erosive status, age, baseline tender joint
count, pain and patient global score), and this could potentially cause confounding. However,
additional multivariate regression analysis adjusting for these potential confounders did not
markedly change the significance levels or effect sizes for the RF status-stratified analyses of
CARD8 (rs2043211), IFNGR2 (rs17882748), IL12B (rs6887695), IL18 (rs187238, rs360719),
TLR5 (rs5744174) or TLR1 (rs4833095) (S6 Table).
Discussion
In this study, we extended the analyses of polymorphisms in genes related to inflammasome-
and interferon-γ pathways. Overall, we successfully genotyped 20 of 23 functional polymor-
phisms, and six SNPs in IL12B, IL18, NLRP3, TLR1 and TLR5 (Table 2) were nominally associ-
ated with EULAR treatment response in RA patients treated with anti-TNF. Furthermore, the
TLR5 polymorphism lacked association among the seropositive patients but was strongly asso-
ciated with response among the seronegative patients.
We chose to analyse at the 0.05 significance level. At this level, we had80% chance to
detect effect sizes between 1.3 and 1.5 assuming an additive genetic model, and effect sizes
between 1.6 and 2.9 assuming a recessive model (MAF between 0.1–0.4). Since multiple testing
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increases the risk of false positive associations, we have also presented associations corrected
for multiple testing (False Discovery Rate, q-value). The association found for TLR5 among
seronegative RA patients was the only that withstood correction for multiple testing.
Since the present study is exploratory, replication in independent cohorts is needed, in par-
ticular, for those found in the stratified analyses. However, the selection of functional polymor-
phisms in genes with a biologically plausible role in RA pathogenesis increases the prior
probability of true associations. The presented work does not provide evidence for causal rela-
tionships between the studied polymorphisms and the altered anti-TNF response because the
associated polymorphisms could also be proxies for other genetic markers.
It should be noted that, due to the design of the study, the time-points of collected response
data vary between 60 and 180 days from treatment onset. When we analysed the subset of
patients with response data at 16±4 weeks (comprising 74% of the patients) in the overall
cohort, associations found for IL12B rs6887695, IL18 rs1946518, and the SNPs in TLR1 and
TLR5 remained nominally associated with similar or higher odds ratios (S5 Table).
The contrasting odds ratios for IL12B rs6887695 heterozygous and homozygous variant
genotypes substantially lower the likelihood of a true association for this polymorphism.
The present study reproduces associations between three gene loci (TLR10/1/6 gene cluster,
NLRP3 and TLR5) (Fig 2) and RA anti-TNF response previously found in independent studies
[4,5,7,18]. TLR1 rs4833095 is located within a cluster of genes encoding TLR–1, TLR–6 and
Fig 1. Odds ratio for association between polymorphisms in IL18,NLRP3, TLR1 and TLR5 and EULAR good/moderate vs. none and good vs.
moderate/non-response, respectively. For TLR5 rs5744174, patients were also stratified on diagnosis based on IgM-RF (seropositive-/seronegative RA).
Log scale, 95% confidence interval.
doi:10.1371/journal.pone.0139781.g001
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Fig 2. Linkage disequilibrium-maps for A)NLRP3, B) TLR5, and C) TLR10/1. Numbers in squares
represent r2. Darker red indicates stronger linkage disequilibrium. Maps were made using Haploview software
version 4.2 and CEPH/CEU HapMap dataset (Phase II+III merged, release 28/ August10). HapMap data were
downloaded by respective genes (TLR5 andNLRP3) and for TLR10/1 data spanning both genes. To simplify
LD-maps, SNPs were selected in the following way: NLRP3: minor allele frequency (MAF) >0.1, Hardy-
Weinberg equilibrium (HW) p-value >0.01, genotype>50%, force include: rs10754558, force exclude #4–29;
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TLR–10 in a 54-kb region on chromosome 4. TLR1 rs4833095 is in modest linkage disequilib-
rium with TLR10 rs11096957 (R2 = 0.52, D’ = 0.94), which was found associated with EULAR
GM vs. N response to anti-TNF treatment in a UK cohort (N = 909) [7]. TLR1 rs4833095 has
been associated with a high peripheral blood mononuclear cell (PBMC) TLR–1 cell surface
expression [19]. Here, we found the homozygous variant genotype associated with a greater
chance of good treatment response to anti-TNF. However, this finding relies on small patient
groups and needs confirmation in an independent and preferably larger cohort.
To our knowledge, this study is the third to show an association between genetic variation
in NLRP3 and anti-TNF treatment response. Mathews et al. found three polymorphisms in
NLRP3 with nominal association with EULAR response with rs4925659 as the most tightly
linked with rs10754558 (D’ = 0.93; r2 = 0.40) [5]. In the same cohort as used in the present
study, we have previously reported the rs4612666 T allele to be associated with a lesser chance
of EULAR GM vs. N response [4]. The two SNPs are not in linkage disequilibrium (D’ = 0.15;
r2 = 0.06), thus not allowing haplotype analysis.
Both rs4612666 and rs10754558 in NLRP3 have been functionally investigated by Hitomi
et al. [20]. In THP–1 cells they found minor alleles of these two polymorphisms to decrease
and increase NLRP3 expression, respectively. Based on this, our results for these two polymor-
phisms seem contradictory since the high expression alleles of the two polymorphisms are
associated with positive and negative treatment response, respectively. However, the in vitro
experiments performed on THP–1 cells may not reflect in vivo conditions in RA patients.
We found two polymorphisms in IL18 associated with anti-TNF treatment response. IL–18
is an interleukin that is activated by the NLRP3 inflammasome, and these results therefore fur-
ther support a role of this pathway for anti-TNF treatment outcome in RA.
The association found for TLR5 confirms the association between a TLR5 gene locus and
EULAR anti-TNF response previously found in a Dutch cohort (n = 182) [18]. In that study,
both rs5744174 and another TLR5 polymorphism (rs2072493) in linkage disequilibrium
(genetic distance: 71bp; D’ = 1; r2 = 0.08) were genotyped (Fig 2). Only rs2072493 was associ-
ated with anti-TNF response. In a Swedish validation cohort (n = 269), these findings could
not be confirmed. Due to different MAFs of these two polymorphisms, they have low tagging
capabilities of each other (r2 = 0.08). The lack of associations for rs5744174 in the Dutch cohort
and for rs2072493 in the Swedish cohort could be caused by the low statistical power, causing
false negative results. Differences in statistical methods may also play a role. Coenen et al. per-
formed unadjusted Fisher’s exact or Chi-square test for analyses of 3x3 tables (EULAR
response groups / genotype counts), and analyses of our data are non-significant when ana-
lysed this way (data not shown). Further, differences in anti-TNF drugs received in the two
cohorts may also be of importance. As an example, the fraction of adalimumab-treated patients
is larger in the Dutch cohort (34% vs. 25%). Our data do suggest a trend for a negative adalimu-
mab response for carriers of the TLR5 variant allele compared to a positive treatment response
found in the overall cohort and among infliximab and etanercept treated patients (S4 Table).
Functional studies of TLR5 rs5744174 have shown that flagellin (a TLR5 ligand) stimulation
results in lower chemokine (C-C motif) ligand (CCL20) production in HEK 293T cells [21]
and reduced IL–6 and IL–1β expression in primary immune cells from healthy homozygous
carriers of the variant allele [10]. Another study reported that anti-TNF treatment decreases
TLR5 (and TLR4) expression among ankylosing spondylitis patients [22], which supports the
hypothesis of TLR5 having a role in the differential anti-TNF response.
TLR5: MAF >0.1, HW p-value >0.01, genotype>50%, force include rs5744176, force exclude # 17–25; TLR10/
1: MAF >0.1, HW p-value >0.01, genotype>50%, force include rs11096957, force exclude #4–58, 98–111.
doi:10.1371/journal.pone.0139781.g002
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Interestingly, post hoc analyses showed that change in patients’ subjective general health
assessment (Δ patient global score) and probably also change in pain score could explain most
of the correlation with the multi-component EULAR response. A recent paper by Coenen et al.
showed that separate components of DAS28, such as tender and swollen joint counts, have a
stronger heritability in pharmacogenetic studies of anti-TNF response than DAS28 itself [23].
Although they did not show this for patient global score assessment, it may be the case for
TLR5 rs5744174. In fact, it is well established that TLRs are central in chronic pain pathogene-
sis [24] and TLR2/3/4/5 deficient mice have reduced neuropathic pain [25]. In a future valida-
tion study of the predictive value of this polymorphism, it will therefore be very relevant to
include analyses adjusting for patient global score and RF status.
Overall, the effects of the associated polymorphisms were too weak to be used as indepen-
dent biomarkers for treatment response but they have a potential use as part of a larger panel
of predictive biomarkers if validated in independent cohorts.
Based on the results from this study, we hypothesize that so far undefined RA sub-pheno-
type(s) not responding to anti-TNF treatment are characterized by increased NLRP3-inflam-
masome activation and increased IL–1β/IL–18 production.
In conclusion, we have reproduced previously published associations between genetic varia-
tion in the TLR10/1/6 gene cluster, TLR5, and NLRP3 loci and response to anti-TNF treatment
in RA. Changes in VAS pain and patient global scores were main factors in the association
found for TLR5. SNPs in IL18 were associated with anti-TNF treatment response, but these
associations need validation in an independent cohort.
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